Evidence map›Paper›PMID 31303524›Full record

ReviewVaccine2019

Vaccines for maternal immunization against Group B Streptococcus disease: WHO perspectives on case ascertainment and case definitions.

Anna C Seale, Carol J Baker, James A Berkley, Shabir A Madhi, Jaume Ordi, Samir K Saha, Stephanie J Schrag, Ajoke Sobanjo-Ter Meulen, Johan Vekemans

Open access · hybridAbstract readReview
In one paragraph

Review in Vaccine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 33 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. CRISPR typing and phage content of colonizing Group BFrontiers in cellular and infection microbiology · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. A group BCell reports. Medicine · 2022
    Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 9 institutions in 8 countries.

Anna C SealeLondon School of Hygiene & Tropical Medicine, Keppel Street, London, UK; College of Health and Medical Sciences, Haramaya University, Harar, Ethiopia; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya. Electronic address: anna.seale@lshtm.ac.uk.
Carol J BakerDepartment of Pediatric, University of Texas Health Science Center McGovern Medical School, Houston, TX, USA.
James A BerkleyKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya; Centre for Tropical Medicine, University of Oxford, Oxford, UK.
Shabir A MadhiMedical Research Council: Respiratory and Meningeal Pathogens Research Unit, & Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases, University of the Witwatersrand, Faculty of Health Sciences, Johannesburg, South Africa.
Jaume OrdiISGlobal, Barcelona Institute of Global Health, Barcelona, Spain; Department of Pathology, Hospital Clinic of Barcelona, Universitat de Barcelona, Barcelona, Spain.
Samir K SahaBangladesh Institute of Child Health, Dhaka, Bangladesh.
Stephanie J SchragNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Ajoke Sobanjo-Ter MeulenBill & Melinda Gates Foundation, Seattle, USA.
Johan VekemansWorld Health Organization, Geneva, Switzerland.
Barcelona Institute for Global Health · ESCenters for Disease Control and Prevention · USChild Health Research Foundation · BDGates Foundation · USHaramaya University · ETKenya Medical Research Institute · KEThe University of Texas Health Science Center at Houston · USUniversity of the Witwatersrand · ZAWorld Health Organization · CH

Funding

Wellcome Trust 205184/Z/16/ZWorld Health Organization 001
6 · The paper itself

Abstract

Group B Streptococcus (GBS) is an important cause of disease in young infants, stillbirths, pregnant and post-partum women. GBS vaccines for maternal immunization are in development aiming to reduce this burden. Standardisation of case definitions and ascertainment methodologies for GBS disease is needed to support future trials of maternal GBS vaccines. Considerations presented here may also serve to promote consistency in observational studies and surveillance, to better establish disease burden. The World Health Organization convened a working group to provide consensus guidance for case ascertainment and case definitions of GBS disease in stillbirths, infants, pregnant and post-partum women, with feedback sought from external stakeholders. In intervention studies, case capture and case ascertainment for GBS disease should be based on antenatal recruitment of women, with active follow-up, systematic clinical assessment, standardised sampling strategies and optimised laboratory methods. Confirmed cases of invasive GBS disease in stillbirths or infants should be included in a primary composite endpoint for vaccine efficacy studies, with GBS cultured from a usually sterile body site (may be post-mortem). For additional endpoints, or observational studies, confirmed cases of GBS sepsis in pregnant and post-partum women should be assessed. Culture independent diagnostic tests (CIDTs) may detect additional presumed cases, however, the use of these diagnostics needs further evaluation. Efficacy of vaccination against maternal and neonatal GBS colonisation, and maternal GBS urinary tract infection could be included as additional, separate, endpoints and/or in observational studies. Whilst the focus here is on specific GBS disease outcomes, intervention studies also present an opportunity to establish the contribution of GBS across adverse perinatal outcomes, including all-cause stillbirth, preterm birth and neonatal encephalopathy.

Indexed as

Maternal HealthWorld Health OrganizationFemaleHumansImmunizationInfantInfant, NewbornInternationalityObservational Studies as TopicPregnancyPregnancy Complications, InfectiousStreptococcal InfectionsStreptococcal VaccinesStreptococcus agalactiaeStreptococcal VaccinesCase ascertainmentCase definitionGroup BStreptococcus agalactiaeVaccine

Identifiers

PMID31303524
PMCPMC6677922
OpenAlexW2962529760

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.